Bryostatin 1 in Treating Patients With Stage IV Breast Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Unequivocal diagnosis of metastatic breast cancer
• Bidimensionally measurable disease
• No uncontrolled CNS metastases
• No disease that is evaluable only, including blastic bone disease, malignant ascites, and malignant pleural effusion
• Hormone receptor status:
• * Not specified
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Menopausal status:
• Not specified
• Performance status:
• SWOG 0-2 OR
• Karnofsky 60-100%
• Life expectancy:
• At least 18 weeks
• Hematopoietic:
• Platelet count at least 50,000/mm\^3
• PT and PTT within normal limits
• Neutrophil count at least 2,000/mm\^3
• Hepatic:
• Bilirubin no greater than 1.2 mg/dL
• Transaminases no greater than 3 times normal
• Renal:
• Creatinine no greater than 1.6 mg/dL OR
• Creatinine clearance at least 70 mL/min
• Other:
• No active infections requiring antibiotics
• No viral hepatitis allowed
• Seronegative for hepatitis B or C
• Not pregnant or nursing
• Fertile patients must use effective contraception during and for 2 months following study participation
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• No concurrent immunotherapy
• Chemotherapy:
• 2 prior chemotherapy regimens for metastatic disease allowed as adjuvant therapy or for advanced disease (may include high dose chemotherapy with stem cell support)
• At least 4 weeks since prior chemotherapy
• At least 6 weeks since prior nitrosourea or mitomycin therapy
• No other concurrent chemotherapy
• Endocrine therapy:
• 2 prior hormonal therapy regimens for metastatic disease as adjuvant therapy or for advanced diseases allowed
• At least 2 weeks since prior hormonal therapy (at least 4 weeks in case of disease progression while receiving hormonal therapy after initial response)
• No concurrent hormonal therapy except oral contraceptives
• No concurrent use of steroids except for management of severe or life- threatening toxic effects arising from bryostatin 1
• Radiotherapy:
• At least 2 weeks since prior radiotherapy
• No concurrent radiotherapy
• Surgery:
• Not specified
• Other:
• No concurrent use of drugs known to interfere with platelet function, such as aspirin or NSAIDs (including ibuprofen)
• No concurrent use of anticoagulants
• At least 2 weeks since prior use of aspirin
• At least 2 days since prior use of NSAIDS
• Concurrent use of acetaminophen to control pain is allowed
• If acetaminophen inadequate for pain control, concurrent use of oral narcotics such as codeine or oxycodone is allowed